These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 19188569)

  • 1. Natalizumab: bound to rebound?
    Schiess N; Calabresi PA
    Neurology; 2009 Feb; 72(5):392-3. PubMed ID: 19188569
    [No Abstract]   [Full Text] [Related]  

  • 2. Is natalizumab overshooting its rebound?
    Fox RJ; Kappos L
    Neurology; 2008 Mar; 70(13 Pt 2):1073-4. PubMed ID: 18362270
    [No Abstract]   [Full Text] [Related]  

  • 3. Lessons for clinical trials from natalizumab in multiple sclerosis.
    Chaudhuri A
    BMJ; 2006 Feb; 332(7538):416-9. PubMed ID: 16484271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natalizumab: targeting alpha4-integrins in multiple sclerosis.
    Engelhardt B; Kappos L
    Neurodegener Dis; 2008; 5(1):16-22. PubMed ID: 18075270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating multiple sclerosis with natalizumab.
    Iaffaldano P; Lucchese G; Trojano M
    Expert Rev Neurother; 2011 Dec; 11(12):1683-92. PubMed ID: 22091593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Natalizumab in multiple sclerosis: unclear patient benefits].
    Schipper JP
    Ned Tijdschr Geneeskd; 2007 Apr; 151(15):852-5. PubMed ID: 17472115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reply to "'Thinking without thinking' about natalizumab and PML".
    Houff S; Berger JR
    J Neurol Sci; 2008 Jan; 264(1-2):198-9; author reply 199. PubMed ID: 17936798
    [No Abstract]   [Full Text] [Related]  

  • 8. Does the flap of a butterfly's wings in Brazil set off a tornado in Texas?--The JC Virus Story in multiple sclerosis.
    Achiron A; Miron S; Shoenfeld Y
    Isr Med Assoc J; 2005 May; 7(5):283-5. PubMed ID: 15909458
    [No Abstract]   [Full Text] [Related]  

  • 9. Recommendations for the selection, treatment, and management of patients utilizing natalizumab therapy for multiple sclerosis.
    Foley J
    Am J Manag Care; 2010 Jun; 16(6 Suppl):S178-83. PubMed ID: 20615054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tysabri raises alarm bells on drug class.
    Sheridan C
    Nat Biotechnol; 2005 Apr; 23(4):397-8. PubMed ID: 15815649
    [No Abstract]   [Full Text] [Related]  

  • 11. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS.
    Vennegoor A; Wattjes MP; van Munster ET; Kriekaart RL; van Oosten BW; Barkhof F; Killestein J; Polman CH
    Neurology; 2011 Feb; 76(6):574-6. PubMed ID: 21300973
    [No Abstract]   [Full Text] [Related]  

  • 12. Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis.
    Dorsey ER; Thompson JP; Noyes K; Dick AW; Holloway RG; Schwid SR
    Neurology; 2007 May; 68(18):1524-8. PubMed ID: 17470756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natalizumab (Tysabri) returns.
    Med Lett Drugs Ther; 2006 Sep; 48(1243):76. PubMed ID: 16977289
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function.
    Khatri BO; Man S; Giovannoni G; Koo AP; Lee JC; Tucky B; Lynn F; Jurgensen S; Woodworth J; Goelz S; Duda PW; Panzara MA; Ransohoff RM; Fox RJ
    Neurology; 2009 Feb; 72(5):402-9. PubMed ID: 19188571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Balancing risk and reward: the question of natalizumab.
    Hauser SL; Johnston SC
    Ann Neurol; 2009 Sep; 66(3):A7-8. PubMed ID: 19810091
    [No Abstract]   [Full Text] [Related]  

  • 16. Natalizumab: new drug. Multiple sclerosis: risky market approval.
    Prescrire Int; 2008 Feb; 17(93):7-10. PubMed ID: 18354844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PML risk and natalizumab: more questions than answers.
    Ransohoff RM
    Lancet Neurol; 2010 Mar; 9(3):231-3. PubMed ID: 20117056
    [No Abstract]   [Full Text] [Related]  

  • 18. Third Tysabri adverse case hits drug class.
    Sheridan C
    Nat Rev Drug Discov; 2005 May; 4(5):357-8. PubMed ID: 15902765
    [No Abstract]   [Full Text] [Related]  

  • 19. Natalizumab and immune cells.
    McFarland HF; Jacobson S
    Arch Neurol; 2006 Oct; 63(10):1366-7. PubMed ID: 17030649
    [No Abstract]   [Full Text] [Related]  

  • 20. [Natalizumab in the treatment of multiple sclerosis].
    Horga A; Horga de la Parte JF
    Rev Neurol; 2007 Sep 1-15; 45(5):293-303. PubMed ID: 17876741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.